MRS was used to examine the aging effects of glutamate in participants with schizophrenia versus healthy controls. The parietal lobe and hippocampus, regions associated with general aging and the pathophysiology of schizophrenia, were assessed. Results revealed that hippocampal glutamate was lower in older adults with schizophrenia versus older controls. In contrast, parietal glutamate was lower in schizophrenia versus controls, irrespective of age group. These results suggest that the hippocampus may be particularly vulnerable to aging in schizophrenia. Interventions that halt hippocampal glutamate decline may be beneficial for patients with schizophrenia.